دورية أكاديمية

Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database

التفاصيل البيبلوغرافية
العنوان: Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database
المؤلفون: Anson, Matthew, Henney, Alex E., Zhao, Sizheng S., Ibarburu, Gema H., Lip, Gregory Y. H., Cuthbertson, Daniel J., Nabrdalik, Katarzyna, Alam, Uazman
المصدر: Anson , M , Henney , A E , Zhao , S S , Ibarburu , G H , Lip , G Y H , Cuthbertson , D J , Nabrdalik , K & Alam , U 2024 , ' Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database ' , Diabetes, Obesity and Metabolism , vol. 26 , no. 7 , pp. 2606-2623 . https://doi.org/10.1111/dom.15576Test
سنة النشر: 2024
المجموعة: Aalborg University (AAU): Publications / Aalborg Universitet: Publikationer
مصطلحات موضوعية: GLP-1 analogue, SGLT2 inhibitor, diabetes complications, systematic review, thiazolidinediones, weight control
الوصف: Aims To evaluate the efficacy and cardiovascular outcomes of combination pioglitazone with either a glucagon-like peptide-1 receptor agonist (GLP-1RA) or a sodium-glucose cotransporter-2 (SGLT2) inhibitor in individuals with type 2 diabetes (T2D) by conducting a systematic review, meta-analysis, and analysis of a large international real-world database. Methods We searched MEDLINE, SCOPUS and Web of Science to identify relevant articles for inclusion (PROSPERO [CRD: 42023483126]). Nineteen studies assessing pioglitazone + SGLT2 inhibitors or GLP-1RAs versus controls were identified, 16 of which were randomized controlled trials. Risk of bias was assessed using Cochrane-endorsed tools and quality of evidence was assessed using GRADE. We additionally performed a retrospective cohort study of all individuals aged 18 years or over with T2D, using the TriNetX platform. We included propensity-score-matched individuals who were treated for at least 1 year with pioglitazone and a GLP-1RA or pioglitazone and an SGLT2 inhibitor, compared against GLP-1RA and SGLT2 inhibitor monotherapy. Outcomes were all-cause mortality, heart failure, chronic kidney disease and composite stroke and transient ischaemic attack. Results The average follow-up in the included studies ranged from 24 to 52 weeks. Combination of pioglitazone with a GLP-1RA reduced glycated haemoglobin (HbA1c) and weight greater than in controls: mean differences −1% (95% confidence interval [CI] −1.27, −0.74) and −1.19 kg (95% CI −1.80, −0.58), respectively. There was no statistically significant difference in systolic blood pressure (SBP) or mortality between groups: mean difference − 1.56 mmHg (95% CI −4.48, 1.35; p = 0.30) and relative risk (RR) 0.29 (95% CI 0.07–1.15; p = 0.08), respectively. Combination of pioglitazone with SGLT2 inhibitors reduced HbA1c, weight and SBP to a greater extent than control treatment: mean differences −0.48% (95% CI −0.67, −0.28), −2.3 kg (95% CI −2.72, −1.88) and −2.4 mmHg (95% CI −4.1, −0.7; p = 0.01), respectively. There was ...
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
العلاقة: https://vbn.aau.dk/da/publications/7afc0e1d-2d2c-43bb-bcd1-f7a1e5adbaaaTest
DOI: 10.1111/dom.15576
الإتاحة: https://doi.org/10.1111/dom.15576Test
https://vbn.aau.dk/da/publications/7afc0e1d-2d2c-43bb-bcd1-f7a1e5adbaaaTest
https://vbn.aau.dk/ws/files/721106889/Anson_et_al._2024_Effect_of_combination_pioglitazone_with_sodium-glucose_cotransporter-2_inhibitors_or_glucagon-like_peptide-1_receptor_agonists_on_outcomes_in_type_2_diabetes_A_systematic_review_meta-analysis_and_real-.pdfTest
http://www.scopus.com/inward/record.url?scp=85189639664&partnerID=8YFLogxKTest
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.13CDB0FD
قاعدة البيانات: BASE